The Atlantic Cancer Research Institute expands its research team and helps stem the brain drain



    MONCTON, NB, Sept. 14 /CNW/ - As its annual general meeting draws to a
close, the Atlantic Cancer Research Institute (ACRI) paints a very positive
picture of its recent activities, in terms of both grants received and the
recruitment and repatriation of personnel.
    "The annual report being tabled today rounds out a decisive year in terms
of the Institute's expansion and sustainability," stated Mr. Denis Losier,
Chairman of the ACRI Board of Directors. "Thanks to the various research
grants we have obtained, as well as the support of the community, the
organization has further consolidated its base and successfully pursued its
mission."
    Over the last year, six new recruits joined the ACRI research team, all
coming from outside the province. Many were New Brunswickers coming back to
the province. "Our institute is increasingly being seen as a hub that attracts
and retains highly talented expertise in the region," commented Dr. Rodney
Ouellette, Chief Executive Officer and Director of discovery for the ACRI.
"This reversal of the brain drain is very positive, not only for our
organization, but for the entire community."
    The Atlantic Cancer Research Institute is pleased to welcome to its ranks
a highly experienced researcher, Dr. David Barnett, a native of Dorchester,
New Brunswick who had been pursuing his career in Ontario in recent years. A
specialist in analytical chemistry, Dr. Barnett is best-known for developing
highly innovative mass spectrometer technology. He has also published more
than 25 peer-reviewed articles on the subject; obtained 16 patents derived
from this technology, and co-founded a company to market it.
    Another high point for the ACRI was the recent acquisition of two new
pieces of cutting-edge high tech equipment that will provide for a more rapid
and precise analysis of the key factors in the development of cancer.
    One of these is a laser capture microdissection system, which allows for
collecting individual cancer cells from a sample without interfering with the
neighboring normal cells. These tools provide for real-time analysis of a
patient's specific cancer, and constitute a more personalized approach to
medicine.
    According to Dr. Ouellette, one important aspect of the Institute is its
role as precursor in the use and application of innovative health
technologies.
    On another front, the ACRI's major fundraising campaign, Discoveries, is
continuing to enjoy great success. To date, 3.3 million dollars have been
raised. The campaign cabinet is confident that the goal of 4 million dollars
will be reached in the very near future.

    The Atlantic Cancer Research Institute (ACRI) is a non-profit
organization founded in 1998 and housed at the Dr. Georges L. Dumont Regional
Hospital in Moncton. With its ultramodern facilities, the ACRI has become a
true centre of excellence in cancer research. Its researchers are pursuing
three main areas of development: early screening; enhanced diagnosis, and
targeted treatment. Through its work, the ACRI is contributing to the global
research aimed at combating cancer.

    /NOTE TO PHOTO EDITORS: A photo accompanying this release is available on
    the CNW Photo Network and archived at http://photos.newswire.ca.
    Additional archived images are also available on the CNW Photo Archive
    website at http://photos.newswire.ca. Images are free to accredited
    members of the media/




For further information:

For further information: Françoise Roy, Director of Communications and
Development, (506) 862-4221, francoiser@canceratl.ca, www.atlanticcancer.ca

Organization Profile

ATLANTIC CANCER RESEARCH INSTITUTE

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890